BMO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
BMO is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 who is impatient and wants to act now. The business fundamentals are improving and the stock is trending above key moving averages, but the current setup is only moderately attractive: momentum is mixed, analyst opinions are mostly neutral-to-mixed, and the options market leans bearish on positioning. I would not call it a clean buy today; it is better suited as a hold or a cautious partial entry rather than an immediate full purchase.
Technically, BMO is in a constructive longer-term trend because SMA_5 > SMA_20 > SMA_200, which supports a bullish structure. However, short-term momentum is not fully confirmed: MACD histogram is -0.142 and negatively expanding, which suggests fading near-term momentum. RSI at 54.766 is neutral and does not indicate an overbought or oversold condition. Price at 152.48 is just above the pivot at 151.358, with resistance at 155.044 and 157.322 and support at 147.672 and 145.394. Overall, the trend is positive but not decisive enough to label it a strong immediate buy.
["Q1 2026 revenue rose 6.51% YoY.", "Q1 2026 net income increased 16.43% YoY.", "Q1 2026 EPS increased 19.79% YoY.", "Recent analyst target increases across RBC, Scotiabank, Desjardins, Jefferies, and National Bank indicate improving expectations.", "Raymond James upgraded the stock to Outperform in February.", "Congress trading data shows 1 purchase and 0 sales in the last 90 days, a positive signal."]
["Barclays downgraded the stock to Underweight in March on valuation concerns.", "Most analyst ratings remain Hold/Sector Perform rather than outright Buy.", "MACD is negative and weakening, showing near-term momentum deterioration.", "Options open interest is bearish with put-call ratio above 1.", "Stock trend data suggests a 60% chance of -1.35% next day and -4.04% over the next month based on similar patterns."]
In Q1 2026, BMO posted solid year-over-year growth: revenue increased to 9.706 billion, up 6.51%, net income rose to 2.409 billion, up 16.43%, and EPS increased to 3.39, up 19.79%. This shows healthy earnings and profitability growth in the latest quarter season, which supports the long-term thesis.
Recent analyst action has trended more positive on price targets, with multiple firms raising targets in late February and early May. However, most firms kept neutral ratings such as Sector Perform, Hold, or Equal Weight, while Barclays downgraded to Underweight due to valuation. Raymond James is the clearest bullish exception with an Outperform upgrade. Wall Street’s pros view is improving earnings, efficiency gains, and ROE expansion potential; the cons view is that much of that progress may already be reflected in the share price.
